H.C. Wainwright Remains a Buy on Coherus Biosciences (CHRS)

In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Coherus Biosciences (CHRSResearch Report), with a price target of $30.00. The company’s shares closed last Friday at $11.83.

Tsao covers the Healthcare sector, focusing on stocks such as Coherus Biosciences, Praxis Precision Medicines, and Roivant Sciences. According to TipRanks, Tsao has an average return of 2.0% and a 40.10% success rate on recommended stocks.

Currently, the analyst consensus on Coherus Biosciences is a Moderate Buy with an average price target of $18.21, implying a 53.93% upside from current levels. In a report released on August 2, Mizuho Securities also assigned a Buy rating to the stock with a $25.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

CHRS market cap is currently $915.9M and has a P/E ratio of (3.98).

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Coherus BioSciences, Inc. is a commercial-stage clinical biologics platform company, which engages in the development and commercialization of biosimilar therapeutics. Its clinical products include pegfilgrastim biosimilar, adalimumab biosimilar, etanercept biosimilar, ranibizumab biosimilar, and aflibercept biosimilar. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.

Read More on CHRS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More